Evidence map›Paper›PMID 40067130›Full record

ArticleCPT: pharmacometrics & systems pharmacology2025

Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB-02) in Patients With Advanced Solid Tumors.

Chengjun Jiang, Fang Ren, Mingfei Zhang, Qiaoyang Lu, Shuqi Zeng, Guang Yang, Yonghong Zhu

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04618393 (A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04618393 phase1 / phase2terminatednot on this map

A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors

TypeinterventionalSponsorShanghai EpimAb Biotherapeutics Co., Ltd.Ran2021 to 2024Enrolled47ConditionsAdvanced Solid TumorsArmsEMB-02
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chengjun JiangHanghai EpimAb Biotherapeutics Co., Ltd, Shanghai EpimAb Biotherapeutics, Shanghai, China.
Fang RenHanghai EpimAb Biotherapeutics Co., Ltd, Shanghai EpimAb Biotherapeutics, Shanghai, China.
Mingfei ZhangHanghai EpimAb Biotherapeutics Co., Ltd, Shanghai EpimAb Biotherapeutics, Shanghai, China.
Qiaoyang LuHanghai EpimAb Biotherapeutics Co., Ltd, Shanghai EpimAb Biotherapeutics, Shanghai, China.
Shuqi ZengHanghai EpimAb Biotherapeutics Co., Ltd, Shanghai EpimAb Biotherapeutics, Shanghai, China.
Guang YangHanghai EpimAb Biotherapeutics Co., Ltd, Shanghai EpimAb Biotherapeutics, Shanghai, China.
Yonghong ZhuHanghai EpimAb Biotherapeutics Co., Ltd, Shanghai EpimAb Biotherapeutics, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fanastomig (also known as EMB-02) is a bispecific antibody targeting programmed cell death protein-1(PD-1) and lymphocyte activation gene-3 (LAG-3), developed for the treatment of advanced solid tumors. A first-in-human (FIH) Phase I study (NCT04618393) evaluated safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and clinical efficacy of Fanastomig in patients with advanced solid tumors. To determine the recommended Phase II dose (RP2D), population pharmacokinetics (PopPK), and exposure and response analysis (E-R) were conducted. The PopPK model, demonstrating good performance, showed no clinically meaningful relationship between areas under the concentration-time curve (AUC) or maximum concentration (C

Indexed as

Antibodies, BispecificAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsNeoplasmsAdultAgedArea Under CurveDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedModels, BiologicalProgrammed Cell Death 1 ReceptorAntibodies, BispecificAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptordose optimizationexposure and responseFanastomiglympahocyte activation gene‐3 (LAG‐3)population pharmacokinetic modelprogrammed cell death protein 1 (PD‐1)receptor occupancy

Identifiers

PMID40067130
PMCPMC12072225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.